venBio Partners — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)
Board seatCorey Goodman· per SEC Form D
Co-investorsAlpha Wave GlobalBioBritvenBio Global StrategicVivo Capital
Cambridge, MA biotech developing single-course in vivo base editing medicines to permanently lower cardiovascular disease risk.
BiotechCambridge, US
Andrew Ashe(Executive Officer)Sekar Kathiresan(Executive Officer, Director)Andrew Bellinger(Executive Officer)
BoardJohn Evans(Director)Anthony Philippakis(Director)inKrishna Yeshwant(Director)in
Co-investorsARCH Venture PartnersF-Prime CapitalGV (Google Ventures)RA CapitalForesite Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.